13 Best Multibagger Stocks to Invest in Now

Page 5 of 13

9. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Upside Potential:           285.81%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company with a pioneering approach to gene science-based medicines. It focuses on developing therapies for neuropathic pain and cardiometabolic diseases, addressing critical unmet medical needs. Lexicon employs precision science to create innovative treatments that aim to significantly improve patient lives. Among its notable products is Sotagliflozin, marketed under the brand name INPEFA, which is specifically designed to reduce cardiovascular risks such as heart failure and type 2 diabetes. This drug represents a substantial advancement in the management of complex cardiovascular conditions.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) distinguishes itself through its unique focus on creating orally-delivered small molecule drugs. These therapies are specifically engineered to target diseases in a way that enhances convenience and accessibility for patients. The company is committed to developing treatments that not only improve health outcomes but also simplify the treatment process for individuals grappling with debilitating conditions. Additionally, Lexicon has fostered strategic collaborations with renowned entities like Viatris Inc. and Bristol-Myers Squibb. These partnerships aim to bolster its drug development capabilities while extending its reach into specialized markets. The company’s collaborative efforts enhance its ability to innovate and deliver differentiated therapeutic options in highly competitive fields.

A testament to its success and strategic decisions, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) latest earnings report for Q1 of 2025 highlighted a revenue of $1.26 million (11.68% higher YoY), surpassing analyst estimates. Over the course of the financial year 2024, the company generated an impressive $97.3 million in revenue, largely driven by the commercial sales of INPEFA, its flagship heart failure treatment. Analysts on Wall Street remain cautiously optimistic, with 50% recommending a “Hold” strategy for the stock. However, the consensus average share price over the next twelve months is projected to be $2.60, offering an upside potential of 285.81%.

Page 5 of 13